Viral susceptibility and the choice of influenza antivirals

Clinical Infectious Diseases

Volumn 47, Issue 3, 2008, Pages 346-348

  Monto, Arnold S ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; MEASLES VACCINE; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR; ANTIVIRUS AGENT; SIALIDASE;

ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; DRUG CHOICE; DRUG EFFICACY; FEVER; HUMAN; IC 50; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; JAPAN; NOTE; OTITIS MEDIA; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS SHEDDING; ANTIVIRAL RESISTANCE; CLINICAL PRACTICE; DRUG ANTAGONISM; DRUG EFFECT; INFLUENZA VIRUS A H1N1;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR; PHYSICIAN'S PRACTICE PATTERNS; ZANAMIVIR;

EID: 47549106504     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/589749     Document Type: Note

References (25)

1. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321:1696-702.
2. Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991; 134:988-97.
3. McKimm-Breschkin J, Trivedi A, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47:2264-72.
4. Von Itzstein M, Wu W-Y, Kok GB, et al. Rational design of potent sialidase-based inhib itors of influenza virus replication. Nature 1993; 363:418-23.
5. Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999; 282:31-5.
6. Hayden FG, Atmar RL, Schilling, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341:1336-43.
7. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283:1016-24.
8. Nicholson KG, Aoki FY, Osterhaus ADME, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet 2000; 355:1845-50.
9. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother 1999; 44:23-9.
10. Kaiser L, Keene ON, Hammond JM, et al. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160:3234-40.
11. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667-72.
12. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127-33.
13. Belshe RB, Mendelman PM, Treanor J, et al. Efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza vaccine in children. N Engl J Med 1998; 338:1405-12.
14. Gubareva LV, Kaiser L, Matrosovich MN, et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001; 183:523-31.
15. Kiso M, Mitamura K, Sakai-Tagawa K, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759-65.
16. Ward P, Small J, Smith P, et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55:i5-21.
17. Ives JAL, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antivir Res 2002; 55:307-17.
18. Herlocher L, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004; 190:1627-30.
19. Monto AS, McKimm-Breschkin J, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50:2395-401.
20. Deyde VM, Xu X, Bright R, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196:249-57.
21. Influenza A(H1N1) virus resistance to oseltamivir-last quarter 2007 to 4 April 2008. Available at: http://www.who.int/csr/disease/influenza/ H1N1ResistanceWeb20080403.pdf. Accessed 9 April 2008.
22. Sugaya N, Tamura D, Yamazaki M, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis 2008; 47:339-45 (in this issue).
23. Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007; 44:197-202.
24. Centers for Disease Control and Prevention. Influenza antiviral use for persons at high risk for influenza complications or who have severe influenza illness. Available at: http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp? AlertNum=00271. Accessed 10 April 2008.
25. Ison, MG, Gubareva LV, Atmar RL, et al. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193:760-64.